Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageDebt RatioDebt to EquityEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested Capital

Gain Therapeutics (GANX) Equity Ratio (2020 - 2025)

Historic Equity Ratio for Gain Therapeutics (GANX) over the last 6 years, with Q3 2025 value amounting to 0.54.

  • Gain Therapeutics' Equity Ratio fell 1315.38% to 0.54 in Q3 2025 from the same period last year, while for Sep 2025 it was 0.54, marking a year-over-year decrease of 1315.38%. This contributed to the annual value of 0.61 for FY2024, which is 1043.45% down from last year.
  • Gain Therapeutics' Equity Ratio amounted to 0.54 in Q3 2025, which was down 1315.38% from 0.38 recorded in Q2 2025.
  • In the past 5 years, Gain Therapeutics' Equity Ratio registered a high of 0.93 during Q1 2021, and its lowest value of 0.38 during Q2 2025.
  • Moreover, its 5-year median value for Equity Ratio was 0.68 (2023), whereas its average is 0.7.
  • As far as peak fluctuations go, Gain Therapeutics' Equity Ratio skyrocketed by 3830.48% in 2021, and later crashed by 3877.86% in 2025.
  • Gain Therapeutics' Equity Ratio (Quarter) stood at 0.89 in 2021, then fell by 12.28% to 0.78 in 2022, then decreased by 13.72% to 0.68 in 2023, then fell by 10.43% to 0.61 in 2024, then fell by 11.03% to 0.54 in 2025.
  • Its Equity Ratio was 0.54 in Q3 2025, compared to 0.38 in Q2 2025 and 0.5 in Q1 2025.